Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors

Int J Clin Pharmacol Ther. 2009 Jan;47(1):58-60. doi: 10.5414/cpp47058.
No abstract available

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacokinetics*
  • Antineoplastic Agents / therapeutic use
  • Biomarkers / blood
  • Biomarkers / chemistry
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • DNA Adducts / blood
  • DNA Adducts / chemistry
  • Dose-Response Relationship, Drug
  • Half-Life
  • Humans
  • Indazoles / administration & dosage
  • Indazoles / chemistry
  • Indazoles / pharmacokinetics*
  • Indazoles / therapeutic use
  • Infusions, Intravenous
  • Leukocytes / chemistry
  • Metabolic Clearance Rate
  • Neoplasms / drug therapy
  • Neoplasms / metabolism*
  • Organometallic Compounds
  • Ruthenium Compounds / administration & dosage
  • Ruthenium Compounds / chemistry
  • Ruthenium Compounds / pharmacokinetics*
  • Ruthenium Compounds / therapeutic use
  • Serum Albumin / analysis
  • Serum Albumin / chemistry
  • Serum Albumin / metabolism
  • Transferrin / analysis
  • Transferrin / chemistry
  • Transferrin / metabolism

Substances

  • Antineoplastic Agents
  • Biomarkers
  • DNA Adducts
  • Indazoles
  • Organometallic Compounds
  • Ruthenium Compounds
  • Serum Albumin
  • Transferrin
  • indazolium trans-(tetrachlorobis(1H-indazole)ruthenate (III))